ADT	androgen deprivation therapy
AKI	acute kidney injury
Bic	bicalutamide
BNIP3	Bcl-2 interacting protein 3
CAB	combined androgen blockade
CVD	cardiovascular diseases
DCFDA	2’,7’-dichlorofluorescin diacetate
DHE	dihydroethidium
DM	diabetes mellitus
DMEM	Dulbecco’s modified Eagle medium
ECAR	extracellular acidification rate
ECL	enhanced chemiluminescence
HIF-1α	hypoxia-inducible factor 1-alpha
KIM-1	kidney injury molecule-1
LDH	lactic dehydrogenase
MMP	mitochondrial membrane potential
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
OCR	oxygen consumption rate
OXPHOS	oxidative phosphorylation
PCa	prostate cancer
RMC	rat mesangial cell
ROS	reactive oxygen species
TEM	transmission electron microscopy